Android Apple

BioCardia Shares More Than Double After FDA Approves Medical Instrument Morph DNA Steerable Introducer

By MarketWatch   |   3 months ago
BioCardia Shares More Than Double After FDA Approves Medical Instrument Morph DNA Steerable Introducer

BioCardia's shares surged in after-hours trading after FDA approval for Morph DNA Steerable Introducer. The product aims to facilitate introducing medical instruments into the heart, with shares trading at $4.79 after closing at $2.20.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.